UCB SA - BNP Paribas Fortis

A11250830/2.25/23 Oct 2009 7
PART I: SUMMARY
This summary must be read as an introduction to the listing and offering prospectus dated 23 October 2009 (the
“Prospectus”) and any decision to invest in the 5.75 per cent. fixed rate bonds due 27 November 2014 (the
“Bonds”) should be based on a consideration of this Prospectus as a whole, including the documents incorporated
by reference. Following the implementation of the relevant provisions of the Prospectus Directive in each Member
State of the European Economic Area (an “EEA State”), no civil liability will attach to the Responsible Persons (as
defined on p. 3 of the Prospectus) in any such Member State solely on the basis of this summary, including any
translation thereof, unless it is misleading, inaccurate or inconsistent when read together with the other parts of
this Prospectus. Full version of this Prospectus is available on the website of the Issuer (www.ucb.com) and the
website of the Luxembourg Stock Exchange (www.bourse.lu). Where a claim relating to the information contained
in this Prospectus is brought before a court in an EEA State, the plaintiff may, under the national legislation of the
EEA State where the claim is brought, be required to bear the costs of translating the Prospectus before the legal
proceedings are initiated.
Terms defined in "Terms and Conditions of the Bonds" below shall have the same meaning where used in this
Summary.
1. BUSINESS DESCRIPTION OF THE ISSUER
UCB S.A. is a Belgian corporation (“naamloze vennootschap”/“société anonyme”) having its registered
office at 60 Allée de la Recherche, 1070 Brussels, Belgium and registered with the register of legal
persons (“rechtspersonenregister”/“registre des personnes morales”) under enterprise number
(“ondernemingsnummer”/“numéro d’entreprise”) VAT-BE 0403.053.608 RLP Brussels.
UCB S.A. was incorporated on 26 May 1925. UCB’s Ordinary Shares have been listed on the Belgian
Stock Exchange (now Euronext Brussels) since incorporation.
The UCB Group is a global biopharmaceutical company, headquartered in Brussels. The UCB Group
develops and markets human pharmaceutical products for the treatment of severe central nervous system
(CNS) and immunology disorders.
The strategy of the UCB Group is driven by its ambition to form a leading global next generation
biopharmaceutical company focused on the treatment of severe diseases. The UCB Group differentiates
itself by focusing on a patient-driven approach to developing treatments for a range of severe CNS and
immunology disorders.
The key marketed products of the UCB Group are Vimpat®, Neupro® and Keppra® (including
Keppra®XR) for CNS diseases. For immunology, the key marketed product is Cimzia®. Other
significant marketed products include Zyrtec®, Xyzal®, Tussionex®, venlafaxine, Nootropil®, Innovair®
and MetadateCD.
The currently marketed products of the UCB Group are supplemented by a research and development
pipeline focusing on the following CNS diseases: epilepsy, diabetic neuropathic pain, restless legs
syndrome and Parkinson’s disease. Research and development is also carried out in the following
immunology disorders: Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, bone loss
disorders and other autoimmune diseases. Through its partnership with Pfizer, UCB also participates in
the over-active bladder disease area. The UCB Group believes that the concentration of its research and
development efforts on a limited range of severe diseases increases the likelihood of significant, high-
A4 - 5.1